Can immunotherapy reinforce chemotherapy efficacy? a new perspective on colorectal cancer treatment

被引:8
作者
He, Xing [1 ]
Lan, Huanrong [2 ]
Jin, Ketao [3 ]
Liu, Fanlong [4 ]
机构
[1] Jinhua Wenrong Hosp, Dept Gastroenterol, Jinhua, Zhejiang, Peoples R China
[2] Hangzhou Canc Hosp, Dept Surg Oncol, Hangzhou, Zhejiang, Peoples R China
[3] Zhejiang Univ, Affiliated Jinhua Hosp, Dept Colorectal Surg, Sch Med, Jinhua, Zhejiang, Peoples R China
[4] Zhejiang Univ, Affiliated Hosp 1, Dept Colorectal Surg, Sch Med, Hangzhou, Zhejiang, Peoples R China
关键词
colorectal cancer; tumor treatment; chemotherapy; immunotherapy; cell therapy; CAR-T-CELLS; THYMIDINE PHOSPHORYLASE EXPRESSION; CONSENSUS MOLECULAR SUBTYPES; IMMUNE CHECKPOINT INHIBITORS; 1ST-LINE TREATMENT; TARGETED THERAPY; PHASE-II; INTRATUMOR HETEROGENEITY; ORAL CAPECITABINE; PLUS IRINOTECAN;
D O I
10.3389/fimmu.2023.1237764
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
As one of the main threats to human life (the fourth most dangerous and prevalent cancer), colorectal cancer affects many people yearly, decreases patients' quality of life, and causes irreparable financial and social damages. In addition, this type of cancer can metastasize and involve the liver in advanced stages. However, current treatments can't completely eradicate this disease. Chemotherapy and subsequent surgery can be mentioned among the current main treatments for this disease. Chemotherapy has many side effects, and regarding the treatment of this type of tumor, chemotherapy can lead to liver damage, such as steatohepatitis, steatosis, and sinus damage. These damages can eventually lead to liver failure and loss of its functions. Therefore, it seems that other treatments can be used in addition to chemotherapy to increase its efficiency and reduce its side effects. Biological therapies and immunotherapy are one of the leading suggestions for combined treatment. Antibodies (immune checkpoint blockers) and cell therapy (DC and CAR-T cells) are among the immune system-based treatments used to treat tumors. Immunotherapy targets various aspects of the tumor that may lead to 1) the recruitment of immune cells, 2) increasing the immunogenicity of tumor cells, and 3) leading to the elimination of inhibitory mechanisms established by the tumor. Therefore, immunotherapy can be used as a complementary treatment along with chemotherapy. This review will discuss different chemotherapy and immunotherapy methods for colorectal cancer. Then we will talk about the studies that have dealt with combined treatment.
引用
收藏
页数:19
相关论文
共 226 条
[1]   The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study [J].
Akdeniz, Nadiye ;
Kaplan, Muhammet Ali ;
Uncu, Dogan ;
Inanc, Mevlude ;
Kaya, Serap ;
Dane, Faysal ;
Kucukoner, Mehmet ;
Demirci, Ayse ;
Bilici, Mehmet ;
Durnali, Ayse Gok ;
Koral, Lokman ;
Sendur, Mehmet Ali Nahit ;
Erol, Cihan ;
Turkmen, Esma ;
Olmez, Omer Fatih ;
Acikgoz, Ozgur ;
Lacin, Sahin ;
Sahinli, Hayriye ;
Urakci, Zuhat ;
Isikdogan, Abdurrahman .
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2021, 36 (06) :1311-1319
[2]   A Review on Cancer Immunotherapy and Applications of Nanotechnology to Chemoimmunotherapy of Different Cancers [J].
Akkin, Safiye ;
Varan, Gamze ;
Bilensoy, Erem .
MOLECULES, 2021, 26 (11)
[3]  
Aldahlawi Alia M, 2022, J Microsc Ultrastruct, V10, P107, DOI 10.4103/jmau.jmau_20_21
[4]   Managing 5FU Cardiotoxicity in Colorectal Cancer Treatment [J].
Anaka, Matthew ;
Abdel-Rahman, Omar .
CANCER MANAGEMENT AND RESEARCH, 2021, 14 :273-285
[5]   CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer [J].
André, T ;
Louvet, C ;
Maindrault-Goebel, F ;
Couteau, C ;
Mabro, M ;
Lotz, JP ;
Gilles-Amar, V ;
Krulik, M ;
Carola, E ;
Izrael, V ;
de Gramont, A .
EUROPEAN JOURNAL OF CANCER, 1999, 35 (09) :1343-1347
[6]   Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial [J].
Antoniotti, Carlotta ;
Rossini, Daniele ;
Pietrantonio, Filippo ;
Catteau, Aurelie ;
Salvatore, Lisa ;
Lonardi, Sara ;
Boquet, Isabelle ;
Tamberi, Stefano ;
Marmorino, Federica ;
Moretto, Roberto ;
Ambrosini, Margherita ;
Tamburini, Emiliano ;
Tortora, Giampaolo ;
Passardi, Alessandro ;
Bergamo, Francesca ;
Kassambara, Alboukadel ;
Sbarrato, Thomas ;
Morano, Federica ;
Ritorto, Giuliana ;
Borelli, Beatrice ;
Boccaccino, Alessandra ;
Conca, Veronica ;
Giordano, Mirella ;
Ugolini, Clara ;
Fieschi, Jacques ;
Papadopulos, Alexia ;
Massoue, Clementine ;
Aprile, Giuseppe ;
Antonuzzo, Lorenzo ;
Gelsomino, Fabio ;
Martinelli, Erika ;
Pella, Nicoletta ;
Masi, Gianluca ;
Fontanini, Gabriella ;
Boni, Luca ;
Galon, Jerome ;
Cremolini, Chiara .
LANCET ONCOLOGY, 2022, 23 (07) :876-887
[7]   HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development [J].
Arab, Atefeh ;
Yazdian-Robati, Rezvan ;
Behravan, Javad .
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2020, 68 (01)
[8]   Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells [J].
Arango, D ;
Wilson, AJ ;
Shi, Q ;
Corner, GA ;
Arañes, MJ ;
Nicholas, C ;
Lesser, M ;
Mariadason, JM ;
Augenlicht, LH .
BRITISH JOURNAL OF CANCER, 2004, 91 (11) :1931-1946
[9]   Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy [J].
Bai, Ziyi ;
Zhou, Yao ;
Ye, Zifan ;
Xiong, Jialong ;
Lan, Hongying ;
Wang, Feng .
FRONTIERS IN IMMUNOLOGY, 2022, 12
[10]   Irinotecan: 25 years of cancer treatment [J].
Bailly, Christian .
PHARMACOLOGICAL RESEARCH, 2019, 148